文献速递儿童青少年精神心境障碍精神分裂症与精神病性障碍

抗精神病药物与儿童及年轻成人死亡率

Antipsychotic Medications and Mortality in Children and Young Adults.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

结果显示,氯丙嗪当量≤100 mg/d或5-17岁儿童中,抗精神病药与死亡风险增加无关;而>100 mg/d时,18-24岁年轻成人死亡风险显著增加,每10万人年额外死亡127.5例,主要与过量和其他意外伤害死亡相关。

要点

  • 氯丙嗪当量≤100 mg/d或5-17岁儿童中,抗精神病药未显著增加死亡风险。
  • >100 mg/d时,18-24岁年轻成人死亡风险显著增加,每10万人年额外死亡127.5例。
  • 高剂量抗精神病药与过量死亡及其他意外伤害死亡显著相关。

核心结论

  • 抗精神病药剂量≤100 mg氯丙嗪当量或5-17岁儿童中,未观察到死亡风险增加。
  • 剂量>100 mg氯丙嗪当量时,18-24岁年轻成人死亡风险显著增加,每10万人年额外死亡127.5例。
  • 高剂量抗精神病药与过量死亡及其他意外伤害死亡显著相关,与非过量自杀死亡或心血管/代谢死亡无关。

研究设计与样本

  • 美国全国回顾性队列研究,纳入医疗补助计划患者,年龄5-24岁,无严重躯体疾病或精神分裂症相关精神病,开始使用研究药物。
  • 暴露为当前使用第二代抗精神病药(按氯丙嗪当量≤100 mg/d或>100 mg/d分层)对比对照药物(α激动剂、托莫西汀、抗抑郁药、心境稳定剂)。

主要发现

  • 抗精神病药剂量≤100 mg与死亡率无显著关联(RD 3.3/10万人年,95%CI -5.1至11.7;HR 1.08,95%CI 0.89-1.32)。
  • 剂量>100 mg与死亡率显著关联(RD 22.4/10万人年,95%CI 6.6-38.2;HR 1.37,95%CI 1.11-1.70)。
  • 高剂量抗精神病药与过量死亡显著相关(RD 8.3/10万人年,95%CI 0-16.6;HR 1.57,95%CI 1.02-2.42)。
  • 高剂量抗精神病药与其他意外伤害死亡显著相关(RD 12.3/10万人年,95%CI 2.4-22.2;HR 1.57,95%CI 1.12-2.22)。

关键数值与推荐

  • 剂量≤100 mg氯丙嗪当量:死亡率RD 3.3/10万人年(95%CI -5.1至11.7),HR 1.08(95%CI 0.89-1.32)。
  • 剂量>100 mg氯丙嗪当量:死亡率RD 22.4/10万人年(95%CI 6.6-38.2),HR 1.37(95%CI 1.11-1.70)。
  • 18-24岁年轻成人剂量>100 mg:死亡率RD 127.5/10万人年(95%CI 44.8-210.2),HR 1.68(95%CI 1.23-2.29)。

临床怎么用

  • 对18-24岁年轻成人处方高剂量(>100 mg氯丙嗪当量)抗精神病药时,需权衡死亡风险,尤其是过量和其他意外伤害风险。
  • 对5-17岁儿童或低剂量(≤100 mg氯丙嗪当量)治疗,未观察到死亡风险显著增加,但仍应定期评估。

局限性

  • 原文未报告严重躯体疾病或精神分裂症相关精神病以外的排除标准细节。
  • 原文未报告随访时长、失访情况或混杂因素控制的具体变量。
  • 原文未报告死因分类的验证方法或潜在错分偏倚。
  • 原文未报告不同抗精神病药个体药物的效应差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dose-related effects of antipsychotic medications may increase mortality in children and young adults. OBJECTIVE: To compare mortality for patients aged 5 to 24 years beginning treatment with antipsychotic vs control psychiatric medications. DESIGN, SETTING, AND PARTICIPANTS: This was a US national retrospective cohort study of Medicaid patients with no severe somatic illness or schizophrenia or related psychoses who initiated study medication treatment. Study data were analyzed from November 2022 to September 2023. EXPOSURES: Current use of second-generation antipsychotic agents in daily doses of less than or equal to 100-mg chlorpromazine equivalents or greater than 100-mg chlorpromazine equivalents vs that for control medications (α agonists, atomoxetine, antidepressants, and mood stabilizers). MAIN OUTCOME AND MEASURES: Total mortality, classified by underlying cause of death. Rate differences (RDs) and hazard ratios (HRs) adjusted for potential confounders with propensity score-based overlap weights. RESULTS: The 2 067 507 patients (mean [SD] age, 13.1 [5.3] years; 1 060 194 male [51.3%]) beginning study medication treatment filled 21 749 825 prescriptions during follow-up with 5 415 054 for antipsychotic doses of 100 mg or less, 2 813 796 for doses greater than 100 mg, and 13 520 975 for control medications. Mortality was not associated with antipsychotic doses of 100 mg or less (RD, 3.3; 95% CI, -5.1 to 11.7 per 100 000 person-years; HR, 1.08; 95% CI, 0.89-1.32) but was associated with doses greater than 100 mg (RD, 22.4; 95% CI, 6.6-38.2; HR, 1.37; 95% CI, 1.11-1.70). For higher doses, antipsychotic treatment was significantly associated with overdose deaths (RD, 8.3; 95% CI, 0-16.6; HR, 1.57; 95% CI, 1.02-2.42) and other unintentional injury deaths (RD, 12.3; 95% CI, 2.4-22.2; HR, 1.57; 95% CI, 1.12-2.22) but was not associated with nonoverdose suicide deaths or cardiovascular/metabolic deaths. Mortality for children aged 5 to 17 years was not significantly associated with either antipsychotic dose, whereas young adults aged 18 to 24 years had increased risk for doses greater than 100 mg (RD, 127.5; 95% CI, 44.8-210.2; HR, 1.68; 95% CI, 1.23-2.29). CONCLUSIONS AND RELEVANCE: In this cohort study of more than 2 million children and young adults without severe somatic disease or diagnosed psychosis, antipsychotic treatment in doses of 100 mg or less of chlorpromazine equivalents or in children aged 5 to 17 years was not associated with increased risk of death. For doses greater than 100 mg, young adults aged 18 to 24 years had significantly increased risk of death, with 127.5 additional deaths per 100 000 person-years.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Ray WA, Fuchs DC, Olfson M, et al. Antipsychotic Medications and Mortality in Children and Young Adults. JAMA Psychiatry. 2024. PMID: 38019523. doi:10.1001/jamapsychiatry.2023.4573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。